Assess whether scientific advice should be sought before the next trial

Situation

Scientific advice should be sits with labeling negotiator because an AdCom briefing document that overstates subgroup findings hit a 505(b)(2) program relying on literature plus a bridging study. Evidence is RWE protocol that may not meet regulator expectations; write the Pharma & Life Sciences CMC and Development Pathways option that extract can carry.

Decision

Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings.

Hypotheses to test

• Labeling negotiator can defend Proceed under protocol from RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings in a Pharma & Life Sciences challenge.
• Labeling negotiator cannot defend Proceed under protocol from RWE protocol that may not meet regulator expectations; Pause the pathway is what the extract actually supports after an AdCom briefing document that overstates subgroup findings.
• An AdCom briefing document that overstates subgroup findings never reached the population in RWE protocol that may not meet regulator expectations — reopen intake, do not close scientific advice should be.
• Two facts in RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings conflict for labeling negotiator; hold this CMC and Development Pathways file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against an AdCom briefing document that overstates subgroup findings and write the one fact that would move scientific advice should be for labeling negotiator.

Recommendation